<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4967">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042273</url>
  </required_header>
  <id_info>
    <org_study_id>PAC-001</org_study_id>
    <nct_id>NCT03042273</nct_id>
  </id_info>
  <brief_title>High Strength Cranberry Supplementation for Prevention of Recurrent Urinary Tract Infection</brief_title>
  <official_title>A Randomised, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of High Strength Cranberry (Pacran®) in Women With Recurrent Urinary Tract Infections (Cystitis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swisse Wellness Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Commonwealth Scientific and Industrial Research Organisation, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swisse Wellness Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a Phase 2, multicenter, placebo-controlled, double-blind,
      parallel-arm study to evaluate the efficacy and safety of High Strength Cranberry (500mg
      Pacran®) in preventing UTI (cystitis) in women with a history of recurrent UTI (rUTI).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of UTI</measure>
    <time_frame>6 months</time_frame>
    <description>cultured confirmed UTIs at a level of &gt;108cfu/L (105cfu/mL)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>High Strength Cranberry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule of Matching Placebo orally daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High Strength Cranberry</intervention_name>
    <description>Softgel capsule</description>
    <arm_group_label>High Strength Cranberry</arm_group_label>
    <other_name>25,000mg Vaccinium macrocarpon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Soy oil to match High Strength Cranberry Softgel Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo (for High Strength Cranberry)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females aged 18-65 years, inclusive

          2. A history of recurrent urinary tract infection defined as ≥3 UTIs in the last year OR
             at least 2 UTIs occurring in the last 6 months. Each infection requires confirmation
             by a health professional and at least one infection confirmed by culture.

          3. Willing to answer questionnaires and comply with the study requirements

          4. Ability to swallow capsules

          5. Provided Written Informed Consent

        Exclusion Criteria:

          1. Microbial growth on urine culture of ≥107 cfu/L (104cfu/mL) within 7 days of Day 1

          2. A history of &gt;5 UTIs in the last 6 months (confirmed by self-report or health
             professional)

          3. Use of antibiotics or antibiotics for prophylaxis within 28 days of Day 1

          4. Use of any antibacterial products, that in the opinion of the Medical Investigator
             may interfere with the study outcomes, within 28 days of Day 1

          5. Regular use of Vaccinium containing products (e.g. all forms of blueberries,
             cranberries, bilberry, lingonberry , etc i.e fruit, dried fruit, pills, juices or
             supplements) within 28 days of Day 1 at the discretion of the Medical Investigator

          6. Presence of an intermittent or indwelling urinary catheter

          7. Anatomical abnormalities of the urinary tract
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females with a history of recurrent UTIs</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Welma Stonehouse, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSIRO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bianca Benassi, PhD</last_name>
    <phone>+61 8 8303 8982</phone>
    <email>Bianca.Benassi@csiro.au</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 2, 2017</lastchanged_date>
  <firstreceived_date>February 1, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
